Answers are grounded in this paper and cite their sources.
Current understanding of maturity-onset diabetes of the young (MODY) has been shaped by phenotype-first studies in predominantly European ancestry cohorts, leaving population-level prevalence and penetrance in a multiancestry population incompletely defined. Using a genotype-first design, we analyzed whole-genome sequencing and clinical data from 374,973 unrelated All of Us participants (42.0% non-European ancestry). We identified pathogenic or likely pathogenic variants in 10 established MODY genes and assessed carrier prevalence, diabetes penetrance, and age-dependent diabetes risk, including comparisons with noncarriers stratified by type 2 diabetes polygenic risk score (T2D PRS) and associations between T2D PRS and diabetes risk among carriers. We identified 370 carriers (0.099%; 1 in 1,013), with similar prevalence among European and African ancestry participants (0.105% in both). Diabetes penetrance was incomplete (13.4% by age 40; 43.5% by age 60) and varied by etiology: highest for GCK (56.0% by age 60), intermediate for HNF genes (HNF1A, HNF1B, and HNF4A; 45.4%), and lowest for non-GCK/HNF genes (ABCC8, INS, KCNJ11, NEUROD1, PDX1, and RFX6; 29.0%). In Cox models, carriers of variants in non-GCK/HNF genes had modestly increased diabetes risk (hazard ratio [HR] 1.64; 95% CI 1.19-2.27), which was numerically lower than among noncarriers in the top 10% of T2D PRS (HR 1.91; 95% CI 1.87-1.95). Higher T2D PRS was also associated with greater diabetes risk among carriers (HR per SD 1.32; 95% CI 1.13-1.56). These findings support equitable consideration of MODY genetic testing across ancestries and highlight substantial heterogeneity in diabetes risk among carriers of pathogenic variants in MODY genes. ARTICLE HIGHLIGHTS: Understanding of maturity-onset diabetes of the young (MODY) has been shaped by phenotype-first, predominantly European ancestry studies. We asked what the prevalence and penetrance of pathogenic MODY variants were in 374,973 unrelated All of Us participants from multiple ancestry groups and whether type 2 diabetes polygenic risk modified diabetes risk. Variants were present in 1 in 1,013, with similar prevalence in European and African ancestry individuals; penetrance varied by etiology, with diabetes risk among some carriers overlapping that of noncarriers with high polygenic risk. Higher polygenic risk was associated with greater risk among carriers. Findings support equitable consideration of MODY testing across ancestries and highlight variation in diabetes risk among carriers.
No takes yet. Share an insight, caveat, or question.
Hasebe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: